GVS S p A : - Interim Report on Operations at 31 March 2026

FierceBiotechNeuroVision acquires fellow dx player Durin Life Sciences

BioPharma DiveFDA hold puts Aardvark Prader-Willi drug in limbo

BioPharma DiveSupreme Court preserves access to abortion pill by mail

BioPharma DiveBiotech leaders campaign for Pazdur; Takeda to lay off 4,500 workers

Endpoints NewsCandel reports prostate cancer drug's long-term data ahead of FDA filing

Endpoints NewsPost-Hoc Live: Makary's out at FDA and what comes next

CellThe immunoproteasome disturbs neuronal metabolism and drives neurodegeneration in multiple sclerosis

FierceBiotechNovartis, amid reorg, cuts ‘select number’ of biomedical research roles

PharmaVoiceSanofi’s vaccine bump; the new FDA commish

Endpoints NewsAardvark's next move after clinical hold; Alumis' verdict on Acelyrin asset

FierceBiotechWhy Model Medicines needs to ‘discover new colors’ in its AI drug discovery quest

Thermo FisherDigital Quality Systems, AI, and the Future of Quality Oversight - Contract Pharma